COMPOSITION
OTRIVIN ADULT DROPS and OTRIVIN ADULT METERED-DOSE SPRAY: 1 ml contains 1 mg of xylometazoline hydrochloride. Preservative: 0,011 % m/v benzalkonium chloride.
Excipients: disodium edetate, disodium phosphate dodecahydrate,
methylhydroxypropyl
-cellulose, purified water, sodium chloride, sodium dihydrogen phosphate dihydrate, sorbitol 70 % (non-crystallising).
PHARMACOLOGICAL CLASSIFICATION
A16.1 Nasal Decongestants
PHARMACOLOGICAL ACTION
OTRIVIN contains xylometazoline, which belongs to the group of the
arylalkyl
imidazolines.
OTRIVIN has a vasoconstrictor action, producing decongestion of the nasal and pharyngeal mucosa when administered locally.
The effect of OTRIVIN sets in within a few minutes and persists for several hours.
INDICATIONS
Decongestion of
naso-pharyngeal
mucosa in colds, sinusitis, otitis media and to facilitate rhinoscopy.
CONTRAINDICATIONS
Hypersensitivity to the ingredients.
Hyperthyroidism.
Ischaemic heart disease.
Patients being treated with monoamine oxidase (MAO) - inhibitors or 10 days after stopping treatment.
OTRIVIN should not be employed in status post transsphenoidal hypophysectomy (or after transnasal or transoral surgical interventions in which the dura mater has been exposed).
WARNINGS and SPECIAL PRECAUTIONS
OTRIVIN should be used with caution in patients with hypertension, cardiovascular disease, narrow-angle glaucoma
and
diabetes mellitus.
OTRIVIN should be used with caution in patients showing a strong reaction to sympathomimetic agents, as evidenced by signs of insomnia, dizziness, etc.
Do not exceed the recommended dose, especially in children and in the elderly.
OTRIVIN should not be employed uninterruptedly for periods exceeding two weeks: prolonged or excessive use may cause rebound congestion. Chronic use may lead to atrophic rhinitis.
INTERACTIONS
Concurrent use of tricyclic or tetracyclic antidepressants may potentiate the systemic effects of xylometazoline.
PREGNANCY AND LACTATION
The use of OTRIVIN during pregnancy is not advisable due to its potential systemic absorption.
OTRIVIN should be used with caution during lactation.
DOSAGE AND DIRECTIONS FOR USE
OTRIVIN ADULT DROP and OTRIVIN ADULT METERED-DOSE SPRAY (1 mg/ml) are for nasal administration only, in adults and children over 12 years of age:
2 to 3 drops of the 1 mg/ml solution into each nostril per application, or one puff from the metered-dose spray, into each nostril per application; a total of 3 applications a day is usually sufficient.
OTRIVIN should be used after blowing the nose.
USE OF OTRIVIN METERED-DOSE SPRAY
Remove the protective cap. Before the first application, perform several pumping motions until an even spray appears in the air.
Insert the nozzle into the nostril and press once firmly on the spray head, and breathe in at the same time. Then withdraw the nozzle before releasing pressure. Repeat the operation in the other nostril. Replace the protective cap.
SIDE EFFECTS
The following side effects have been encountered:
Rebound congestion after discontinuation. A burning sensation in the nose and throat, local irritation, nausea, headache, dryness of the nasal mucosa, epistaxis, anosmia, dizziness, palpitations
and
insomnia.
Less frequently: Skin rash or transient visual disturbances.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Signs
In instances of accidental poisoning in children, the clinical picture may be marked chiefly by signs such as acceleration and irregularity of the pulse, elevated blood pressure and sometimes clouding of consciousness, sweating, drowsiness, coma, convulsions, circulatory collapse.
Treatment
Symptomatic treatment under medical supervision is indicated.
IDENTIFICATION
Drops and Metered-Dose Spray: Clear,
colourless
solution.
PRESENTATION
OTRIVIN ADULT DROPS (1 mg/ml solution):
Polyethylene dropper bottles containing 10 ml.
OTRIVIN ADULT METERED-DOSE SPRAY (1 mg/ml solution):
Polyethylene metered-dose spray bottle containing 10 ml.
STORAGE INSTRUCTIONS
OTRIVIN ADULT DROPS: Store at or below 25 °C.
OTRIVIN ADULT METERED- DOSE SPRAY: Store at or below 30 °C.
Keep out of the reach of children.
REGISTRATION NUMBERS
OTRIVIN ADULT DROPS and OTRIVIN ADULT METERED-DOSE SPRAY 1 mg/ml:
H/16.1/1382
Download product information